[go: up one dir, main page]

DK0686045T3 - Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof - Google Patents

Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof

Info

Publication number
DK0686045T3
DK0686045T3 DK94909647T DK94909647T DK0686045T3 DK 0686045 T3 DK0686045 T3 DK 0686045T3 DK 94909647 T DK94909647 T DK 94909647T DK 94909647 T DK94909647 T DK 94909647T DK 0686045 T3 DK0686045 T3 DK 0686045T3
Authority
DK
Denmark
Prior art keywords
pct
stabilization
adjuvant
organic solvent
polypeptides
Prior art date
Application number
DK94909647T
Other languages
English (en)
Inventor
Jeffrey L Cleland
Andrew J S Jones
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0686045T3 publication Critical patent/DK0686045T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK94909647T 1993-02-23 1994-02-17 Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof DK0686045T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2142193A 1993-02-23 1993-02-23
PCT/US1994/001666 WO1994019020A1 (en) 1993-02-23 1994-02-17 Excipient stabilization of polypeptides treated with organic solvents

Publications (1)

Publication Number Publication Date
DK0686045T3 true DK0686045T3 (da) 2001-03-05

Family

ID=21804127

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94909647T DK0686045T3 (da) 1993-02-23 1994-02-17 Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof

Country Status (17)

Country Link
US (3) US5589167A (da)
EP (1) EP0686045B1 (da)
JP (1) JP3698721B2 (da)
CN (1) CN1108823C (da)
AT (1) ATE197550T1 (da)
AU (1) AU685784B2 (da)
CZ (1) CZ296649B6 (da)
DE (1) DE69426292T2 (da)
DK (1) DK0686045T3 (da)
ES (1) ES2153418T3 (da)
GR (1) GR3035383T3 (da)
IL (1) IL108713A (da)
NZ (1) NZ262634A (da)
PT (1) PT686045E (da)
RU (1) RU2143889C1 (da)
WO (1) WO1994019020A1 (da)
ZA (1) ZA941239B (da)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2145418A1 (en) 1992-09-29 1994-04-14 John S. Patton Pulmonary delivery of active fragments of parathyroid hormone
WO1995024183A1 (en) 1994-03-07 1995-09-14 Inhale Therapeutic Systems Methods and compositions for pulmonary delivery of insulin
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
EP0782398A1 (en) 1994-09-22 1997-07-09 Quadrant Holdings Cambridge Limited Compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US6964771B1 (en) * 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
IL122385A (en) * 1995-06-07 2001-01-11 Alkermes Inc Composition for sustained release of human growth hormone
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CN102416176A (zh) * 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
DK0889722T3 (da) 1996-03-28 2003-02-10 Takeda Chemical Industries Ltd Præparat med forsinket frigivelse og fremstilling deraf
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
EP0909175B1 (en) * 1996-07-03 2003-06-04 Alza Corporation Non-aqueous protic peptide formulations
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
AU7871298A (en) 1996-12-20 1998-07-17 Takeda Chemical Industries Ltd. Method of producing a sustained-release preparation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
IL134084A0 (en) * 1997-07-18 2001-04-30 Infimed Inc Biodegradable macromers for the controlled release of biologically active substances
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
WO1999047174A1 (en) * 1998-03-18 1999-09-23 Cambridge Biostability Limited Amorphous glasses for stabilising sensitive products
ES2288018T3 (es) * 1998-04-03 2007-12-16 Novartis Vaccines And Diagnostics, Inc. Formulaciones inyectables de igf que contienen succinato como tampon.
EP1071445A2 (en) * 1998-04-17 2001-01-31 Angiogenix, Incorporated Therapeutic angiogenic factors and methods for their use
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6190701B1 (en) 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
GB9910975D0 (en) * 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
US6566329B1 (en) * 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US6102896A (en) * 1999-09-08 2000-08-15 Cambridge Biostability Limited Disposable injector device
US7651703B2 (en) * 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
AU2001233180A1 (en) * 2000-02-10 2001-08-20 Alkermes Controlled Therapeutics, Inc. Method of preparing a sustained release composition
IL152360A0 (en) 2000-04-19 2003-05-29 Genentech Inc Sustained release formulations
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1280520B2 (en) 2000-05-10 2018-03-21 Novartis AG Phospholipid-based powders for drug delivery
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
EP1309312A2 (en) 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
ATE450253T1 (de) * 2000-10-13 2009-12-15 Cambridge Biostability Ltd Pharmazeutische flüssige suspensionen
US20040109827A1 (en) * 2000-11-29 2004-06-10 Satomi Onoue Powdery preparations and proecss for producing the same
US20040022861A1 (en) * 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
JP4724354B2 (ja) * 2001-02-23 2011-07-13 ジェネンテック， インコーポレイテッド 注射用の崩壊性ポリマー
IL159048A0 (en) 2001-06-21 2004-05-12 Genentech Inc Sustained release formulation
GB0116074D0 (en) * 2001-06-29 2001-08-22 Univ Strathclyde Nanoparticle structures
US7615234B2 (en) * 2001-09-11 2009-11-10 Glide Pharmaceutical Technologies Limited Drug delivery technology
GB2379390B (en) * 2001-09-11 2005-01-26 Caretek Medical Ltd A novel drug delivery technology
ATE508735T1 (de) 2001-12-19 2011-05-15 Novartis Ag Pulmonale verabreichung von aminoglykosiden
AU2003221808A1 (en) * 2002-04-05 2003-10-27 Powerzyme, Inc. Analyte sensor
AU2003230320A1 (en) * 2002-05-09 2003-11-11 Peptron Co., Ltd Sustained release formulation of protein and preparation method thereof
GB2421689B (en) 2002-08-05 2007-03-07 Caretek Medical Ltd Drug delivery system
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
CN100444848C (zh) * 2002-09-27 2008-12-24 特里梅里斯公司 HIV gp41-衍生肽的改善用药的药物组合物
AU2003286472A1 (en) 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US9376479B2 (en) * 2002-12-31 2016-06-28 Anjinomoto Althea, Inc. Human growth hormone crystals and methods for preparing them
MXPA05007182A (es) * 2002-12-31 2006-04-07 Altus Pharmaceuticals Inc Complejos de cristales de proteina y polimeros ionicos.
US20040197413A1 (en) * 2003-04-04 2004-10-07 Genteric, Inc. Spray dry coacervation systems and methods
DE10320609A1 (de) * 2003-05-08 2004-12-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Sprühgefriergranulate mit verbesserter Homogenität der Eigenschaftsverteilung und Verfahren zu deren Herstellung
US7090433B2 (en) * 2003-10-07 2006-08-15 Steve Searby Underground cable laying apparatus
US20050095320A1 (en) * 2003-10-29 2005-05-05 Richard Botteri [An Isotonic Sports Drink for Female Athletes Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Nutrition During Execise and Competition]
US20050100636A1 (en) * 2003-11-10 2005-05-12 Megan Botteri [A Low-Calorie Sports Drink For Physically Active Women That is Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Replacing Electrolytes Lost During Periods of Physical Activity]
BRPI0418304A (pt) * 2004-01-07 2007-05-02 Trimeris Inc peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv
ES2375802T3 (es) * 2004-04-15 2012-03-06 Alkermes Pharma Ireland Limited Dispositivo de liberación sostenida a base de pol�?mero.
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
US7133638B2 (en) * 2004-11-18 2006-11-07 Xerox Corporation Scanning method and an image-processing device including the same
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
GB2422784A (en) * 2005-02-07 2006-08-09 Caretek Medical Ltd Disposable assembly comprising a needle or stylet
NZ561137A (en) * 2005-03-08 2011-09-30 Pharmacia & Upjohn Co Llc Stable anti-CTLA-4 antibody compositions with chelating agents
CN100336557C (zh) * 2005-05-11 2007-09-12 北京双鹭药业股份有限公司 一种生长抑素的水溶液制剂、其制备方法及应用
CN100337684C (zh) * 2005-05-11 2007-09-19 北京双鹭药业股份有限公司 一种胸腺五肽的水溶液制剂、其制备方法及应用
CN100342909C (zh) * 2005-05-11 2007-10-17 北京双鹭药业股份有限公司 一种胸腺素α1的水溶液制剂、其制备方法及应用
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
US9309316B2 (en) * 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
NZ569108A (en) * 2005-12-20 2011-09-30 Bristol Myers Squibb Co Formulations of CTLA4Ig stabilised using sugars
EP1976551A4 (en) * 2005-12-23 2009-12-30 Altus Pharmaceuticals Inc COMPOSITIONS COMPRISING COMPLEX PROTEIN CRYSTALS BY POLYCATIONS AND PROCESSING METHOD THEREOF
CN101415723B (zh) 2006-02-02 2014-06-25 特里梅里斯公司 具有改良生物学特性的hiv融合抑制肽
US9156950B2 (en) * 2006-03-13 2015-10-13 Naturin Gmbh & Co. Collagen powder and collagen-based thermoplastic composition for preparing conformed articles
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
WO2008118133A2 (en) 2006-09-26 2008-10-02 Trustees Of Tufts College Silk microspheres for encapsulation and controlled release
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
DK2486916T3 (da) * 2006-12-18 2015-06-15 Ajinomoto Althea Inc Formuleringer med humant væksthormon
ATE516814T1 (de) * 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
DK2148691T3 (da) 2007-02-05 2015-08-17 Apellis Pharmaceuticals Inc Compstatinanaloger til anvendelse i behandingen af inflammatoriske tilstande i åndedrætssystemet
WO2008124013A1 (en) * 2007-04-03 2008-10-16 Trimeris, Inc. Novel formulations for delivery of antiviral peptide therapeutics
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
KR20100017667A (ko) * 2007-06-01 2010-02-16 노보 노르디스크 에이/에스 안정한 비-수성의 약학 조성물
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
WO2009020744A1 (en) 2007-08-07 2009-02-12 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations comprising gdf-5 in aqueous acidic solution
JP2010540528A (ja) * 2007-09-25 2010-12-24 トリメリス，インコーポレーテッド 治療的抗ウイルス性ペプチドの新規合成方法
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
PL2910570T3 (pl) 2008-03-18 2017-06-30 Novo Nordisk A/S Stabilizowane względem proteaz, acylowane analogi insuliny
EP2276458A1 (en) * 2008-04-14 2011-01-26 Advanced Technologies and Regenerative Medicine, LLC Liquid buffered gdf-5 formulations
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
UA106606C2 (uk) * 2009-03-16 2014-09-25 Родія Оперейшнс Стабілізована біоцидна композиція
US20120070427A1 (en) 2009-06-01 2012-03-22 Trustees Of Tufts College Vortex-induced silk fibroin gelation for encapsulation and delivery
RU2431496C2 (ru) * 2009-09-15 2011-10-20 Общество С Ограниченной Ответственностью "Герофарм" Инъекционная лекарственная форма для лечения острого ишемического инсульта и черепно-мозговой травмы, способ ее изготовления и применение
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
ES2765418T3 (es) 2010-03-01 2020-06-09 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
US9603971B2 (en) 2010-03-05 2017-03-28 Trustees Of Tufts College Silk-based ionomeric compositions
GB201004072D0 (en) 2010-03-11 2010-04-28 Turzi Antoine Process, tube and device for the preparation of wound healant composition
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP4088736A1 (en) 2011-10-25 2022-11-16 Prothena Biosciences Limited Humanized anti-amyloid antibody formulations and methods
WO2013096835A1 (en) * 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
WO2013112897A1 (en) 2012-01-27 2013-08-01 The Regents Of The University Of California Stabilization of biomolecules using sugar polymers
KR20150002777A (ko) 2012-04-11 2015-01-07 노보 노르디스크 에이/에스 인슐린 제제
WO2014035798A1 (en) 2012-08-30 2014-03-06 Sanofi Silk lyogels for sustained release of protein therapeutics and methods of making and uses
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN106456695B (zh) * 2014-04-28 2019-11-12 卫材R&D管理有限公司 Hgf的冻干配制品
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2987766A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
JP2017110001A (ja) * 2015-12-16 2017-06-22 株式会社 資生堂 タブレット型凍結乾燥化粧料
RU2747977C2 (ru) 2016-03-17 2021-05-18 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ получения активного фактора роста гепатоцитов (hgf)
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
JP2019528248A (ja) * 2016-07-18 2019-10-10 ティシュージェン， インク． 生体分子の立体配座及び構造健全性を維持するための方法及び組成物
CN115154591B (zh) 2016-12-16 2023-04-14 诺和诺德股份有限公司 含胰岛素的药物组合物
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
JP6404405B1 (ja) * 2017-06-14 2018-10-10 株式会社 資生堂 タブレット型凍結乾燥化粧料
CN110769810B (zh) * 2017-06-19 2023-08-01 株式会社资生堂 片剂型冷冻干燥化妆品
TWI787186B (zh) * 2017-06-19 2022-12-21 日商資生堂股份有限公司 錠型凍結乾燥化妝料
CN108169499A (zh) * 2017-11-30 2018-06-15 成都斯马特科技有限公司 一种基于生化试剂盘进行凝血分析的方法
CN112739366B (zh) * 2018-09-14 2024-08-30 卡拉治疗学股份有限公司 κ阿片受体激动剂的口服配制品
US12440835B2 (en) 2019-01-21 2025-10-14 Vias Partners, Llc Methods, systems and apparatus for separating components of a biological sample
WO2021087222A1 (en) 2019-10-31 2021-05-06 Eclipse Medcorp, Llc Systems, methods and apparatus for separating components of a sample
EP4415688A2 (en) * 2022-02-01 2024-08-21 Ocular Therapeutix, Inc. A controlled release implant for biologics and corresponding methods of treatment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3664963A (en) * 1969-10-22 1972-05-23 Balchem Corp Encapsulation process
IT1103817B (it) * 1978-06-27 1985-10-14 Guaber Spa Composizione deodorante granulare per posacenere
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
EP0193917A3 (en) * 1985-03-06 1987-09-23 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration
EP0229810B1 (en) * 1985-07-09 1991-10-16 Quadrant Bioresources Limited Protection of proteins and the like
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JP2526589B2 (ja) * 1986-08-08 1996-08-21 武田薬品工業株式会社 ペプチド含有マイクロカプセルおよびその製造法
US5312745A (en) * 1987-06-18 1994-05-17 Chromogenix Ab Determination of components active in proteolysis
ATE82506T1 (de) * 1987-08-21 1992-12-15 Imcera Group Inc Stabilisierung von wachstumshormonen.
WO1989003671A1 (fr) * 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Preparation a liberation entretenue
GB8801338D0 (en) * 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
SU1599019A1 (ru) * 1988-02-08 1990-10-15 Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств Способ получени лиофилизата
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
AT392079B (de) * 1988-03-11 1991-01-25 Voest Alpine Ind Anlagen Verfahren zum druckvergasen von kohle fuer den betrieb eines kraftwerkes
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5039540A (en) * 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5312705A (en) * 1990-07-27 1994-05-17 Matsushita Electric Industrial Co., Ltd. Photosensitive materials for electrophotography having a double-layer structure of a charge generation layer and a charge transport layer
AU1442592A (en) * 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
FR2673843B1 (fr) * 1991-03-14 1995-01-13 Centre Nat Rech Scient Composition pharmaceutique implantable, bioresorbable a base de poly(acide lactique), destinee a mettre en óoeuvre une antibiotherapie interne locale.
DK0724431T3 (da) * 1993-10-22 2003-01-06 Genentech Inc Fremgangsmåder og sammensætninger til mikroindkapsling af adjuvanser
ATE224184T1 (de) * 1993-10-22 2002-10-15 Genentech Inc Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
AU8017494A (en) * 1993-10-22 1995-05-08 Genentech Inc. Method for preparing microspheres comprising a fluidized bed drying step

Also Published As

Publication number Publication date
DE69426292D1 (de) 2000-12-21
EP0686045A1 (en) 1995-12-13
GR3035383T3 (en) 2001-05-31
NZ262634A (en) 1997-02-24
ES2153418T3 (es) 2001-03-01
DE69426292T2 (de) 2001-05-17
PT686045E (pt) 2001-04-30
US5753219A (en) 1998-05-19
IL108713A (en) 1999-12-22
AU685784B2 (en) 1998-01-29
ZA941239B (en) 1995-08-23
EP0686045B1 (en) 2000-11-15
US5804557A (en) 1998-09-08
US5589167A (en) 1996-12-31
CZ296649B6 (cs) 2006-05-17
AU6241294A (en) 1994-09-14
CN1118143A (zh) 1996-03-06
ATE197550T1 (de) 2000-12-15
WO1994019020A1 (en) 1994-09-01
IL108713A0 (en) 1994-05-30
JPH08507064A (ja) 1996-07-30
RU2143889C1 (ru) 2000-01-10
JP3698721B2 (ja) 2005-09-21
CN1108823C (zh) 2003-05-21
CZ212795A3 (en) 1996-02-14

Similar Documents

Publication Publication Date Title
DK0686045T3 (da) Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof
TW263423B (da)
IT1270882B (it) Oligopeptidi ad attivita' fungicida
WO2001018032A3 (en) Dolastatin peptides
DK1351703T3 (da) Anvendelse af et polypeptid omfattende det ekstracellulære domæne af IL-20RA og IL-20RB til behandling af inflammation
FI954601A7 (fi) Rekombinanttisia alfavirusvektoreita
IL110804A (en) Triphenyl- methylthiazolidine-2, 4-dione derivatives and processes utilizing the same
ES2084347T3 (es) Derivados de 5-heteroil-indol.
DE59409837D1 (de) o-Hydroxyphenyl-s-triazine enthaltende stabilisierte Polymere
NO942363L (no) Hypoglycemiske midler
ATE200089T1 (de) Dimerdiol-modifizierte uretdion- pulverlackvernetzer
DK1027348T3 (da) 2-(2'-hydroxyphenyl)benzotriazoler anvendt som UV-stabilisatorer
DE69131667D1 (de) Proteinkinase-c-modulatoren mit entzündungshemmender und antiviraler aktivität
NO910522D0 (no) Fremgangsmaate for forhindring av "blomstring" paa mineralske substrater, samt betongstein som er beskyttet ved hjelpav fremgangsmaaten.
FI933719L (fi) 4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol
NO912293D0 (no) Magnetometer basert paa optisk pumping med bruk av kontrollert polarisasjon.
NO954892L (no) Heterosyklisk kjemi
FI915125L (fi) Synergistiska kombinationer av idopropargylfoereningar med hexahydro-1,3,5-tris (2-hydroxietyl)-s -triazin foer kontroll av svamp- och bakterietillvaext i metallbearbetningsvaetskor.
FR2689120B1 (fr) Procédé de stabilisation de mâchefer.
NO910357D0 (no) Innretning til feilmoensterregenerering ved "soft"-desisjonsdekoding av blokkoder.
ATE154054T1 (de) Stabilisiertes 1,1-dichloro-1-fluoroäthan
ITMI911604A1 (it) Procedimento per la preparazione della n- (2, 6-diclorofenil) -n-fenil-n-(cloroacetil)-ammina.
DK0431331T3 (da) Varmehærdbare stofblandinger
NO981707L (no) Xylanase, oligonukleotidsekvens som koder for xylanase og anvendelse derav
MY107451A (en) Cloning and expression of a rhoptry associated protein of p.falciparum